1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > EpiCast Report: Dyslipidemia - Epidemiology Forecast to 2023

EpiCast Report: Dyslipidemia - Epidemiology Forecast to 2023

Summary

Dyslipidemia is a condition in which one or more of the serum lipid levels are abnormal. It is a well-established risk factor for cardiovascular disease, and the burden of morbidity, mortality, and medical costs arising from dyslipidemia is substantial.

GlobalData epidemiologists forecast that the total prevalent cases of dyslipidemia in the 8MM will increase from 572,418,492 total prevalent cases in 2013, to 685,905,635 total prevalent cases in 2023, at an Annual Growth Rate (AGR) of 1.99%. All markets will see an increase in the total prevalent cases of dyslipidemia at varying AGRs, except for Germany, which will see a decrease. The 8MM had an estimated 3,339,447 total prevalent cases of FH in 2013, and the number of total prevalent cases of FH is expected to increase to 4,365,831 by 2023, at an AGR of 3.07%. All markets will see an increase in the total prevalent cases of FH at varying AGRs, except for Japan, which will see a decrease. Additionally, GlobalData epidemiologists forecast that the total prevalent cases of increased LDLc in the 8MM will increase from 345,008,543 total prevalent cases in 2013 to 411,737,455 total prevalent cases in 2023, at an AGR of 1.93%. All markets will see an increase in the total prevalent cases of increased LDLc at varying AGRs, except for Germany, which will see a decrease. The 8MM had an estimated 10,777,756 total prevalent cases of very high TG (=500mg/dL) in 2013, and the number of total prevalent cases of very high TG is expected to increase to 12,746,492 by 2023, at an AGR of 1.83%. All markets will see an increase in the total prevalent cases of very high TG at varying AGRs, except for Germany and Japan, which will see a decrease.

GlobalData epidemiologists used comprehensive, country-specific data from population based national health surveys such as NHANES in the US, the HSE in the UK, and the CHNS in urban China, in addition to data from peer-reviewed journal articles, to arrive at a meaningful, in-depth analysis and forecast for the total prevalent cases of dyslipidemia, and other therapeutically significant patient populations including the total prevalent cases of increased LDLc and very high TG (=500mg/dL). For all the 8MM, the total prevalent cases of dyslipidemia, increased LDLc, and very high TG (=500mg/dL) were segmented by age and sex, which facilitates an understanding of the distribution of disease within the population, and informs strategies to improve the management of disease.

Scope

- The Dyslipidemia EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for dyslipidemia in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and China [urban]). It includes a 10-year epidemiological forecast for the total prevalent cases of dyslipidemia (defined as: increased low-density lipoprotein cholesterol [LDLc], high triglycerides [TG] [=200mg/dL], or low levels of high-density lipoprotein cholesterol [HDLc]), as well as the total prevalent cases of increased LDLc (=115mg/dL to =160mg/dL based on country-specific cut-offs), and very high TG (=500mg/dL), segmented by sex and age (in 10-year intervals beginning at 20 years and ending at =70 years). Additionally, the forecast provides the total prevalent cases of familial hypercholesterolemia (FH) in these markets.
- The dyslipidemia epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to buy

- Develop business strategies by understanding the trends shaping and driving the global dyslipidemia market.
- Quantify patient populations in the global dyslipidemia market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for dyslipidemia therapeutics in each of the markets covered.

Table Of Contents

EpiCast Report: Dyslipidemia - Epidemiology Forecast to 2023
1 Table of Contents

2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 11
2.3 Upcoming Related Reports 12
3 Epidemiology 13
3.1 Disease Background 13
3.2 Risk Factors and Comorbidities 14
3.3 Global Trends 15
3.3.1 US 16
3.3.2 5EU 16
3.3.3 Asia 18
3.4 Forecast Methodology 19
3.4.1 Sources Used 27
3.4.2 Sources Not Used 33
3.4.3 Forecast Assumptions and Methods 34
3.5 Epidemiological Forecast for Dyslipidemia (2013-2023) 60
3.5.1 Total Prevalent Cases of Dyslipidemia 60
3.5.2 Age-Specific Total Prevalent Cases of Dyslipidemia 62
3.5.3 Sex-Specific Total Prevalent Cases of Dyslipidemia 63
3.5.4 Age-Standardized Total Prevalence of Dyslipidemia 65
3.6 Epidemiological Forecast for Familial Hypercholesterolemia (2013-2023) 66
3.6.1 Total Prevalent Cases of Familial Hypercholesterolemia 66
3.7 Epidemiological Forecast for Increased LDLc (2013-2023) 67
3.7.1 Total Prevalent Cases of Increased LDLc 67
3.7.2 Age-Specific Total Prevalent Cases of Increased LDLc 69
3.7.3 Sex-Specific Total Prevalent Cases of Increased LDLc 72
3.7.4 Age-Standardized Total Prevalence of Increased LDLc 73
3.8 Epidemiological Forecast for Very High TG (?500mg/dL) (2013-2023) 74
3.8.1 Total Prevalent Cases of Very High TG (?500mg/dL) 74
3.8.2 Age-Specific Total Prevalent Cases of Very High TG (?500mg/dL) 76
3.8.3 Sex-Specific Total Prevalent Cases of Very High TG (?500mg/dL) 77
3.8.4 Age-Standardized Total Prevalence of Very High TG (?500mg/dL) 79
3.9 Discussion 79
3.9.1 Epidemiological Forecast Insight 79
3.9.2 Limitations of the Analysis 81
3.9.3 Strengths of the Analysis 82
4 Appendix 83
4.1 Bibliography 83
4.2 About the Authors 89
4.2.1 Epidemiologists 89
4.2.2 Reviewers 89
4.2.3 Acting Director of Epidemiology 90
4.2.4 Global Head of Healthcare 91
4.3 About GlobalData 92
4.4 About EpiCast 92
4.5 Disclaimer 93

1.1 List of Tables

Table 1: Risk Factors and Comorbidities for Dyslipidemia 15
Table 2: Overview of the Total Prevalence of Low HDLc in the 5EU 18
Table 3: NCEP-ATP III Classification of LDLc, TG, and HDLc 20
Table 4: Simon Broome Diagnostic Criteria for FH 21
Table 5: LDLc Based Definition of FH 21
Table 6: Sources of Total Prevalence Data for FH in the 8MM 22
Table 7: Sources of Total Prevalence Data for Increased LDLc in the 8MM 23
Table 8: Sources of Total Prevalence Data for High TG (?200mg/dL) in the 8MM 24
Table 9: Sources of Total Prevalence Data for Very High TG (?500mg/dL) in the 8MM 25
Table 10: Sources of Total Prevalence Data for Low HDLc in the 8MM 26
Table 11: 8MM, Sources Not Used in the Epidemiological Analysis of Dyslipidemia 34
Table 12: 8MM, Total Prevalent Cases of Dyslipidemia, Both Sexes, Ages ?20 Years, N, 2013-2023 61
Table 13: 8MM, Age-Specific Total Prevalent Cases of Dyslipidemia, Both Sexes, N (Row %), 2013 62
Table 14: 8MM, Sex-Specific Total Prevalent Cases of Dyslipidemia, Ages ?20 Years, N (Row %), 2013 64
Table 15: 8MM, Total Prevalent Cases of Familial Hypercholesterolemia, Both Sexes, Ages ?20 Years, N, 2013-2023 66
Table 16: 8MM, Total Prevalent Cases of Increased LDLc* (?115mg/dL to ?160mg/dL), Both Sexes, Ages ?20 Years, N, 2013-2023 68
Table 17: 8MM, Age-Specific Total Prevalent Cases of Increased LDLc* (?115mg/dL to ?160mg/dL), Both Sexes, N (Row %), 2013 70
Table 18: 8MM, Sex-Specific Total Prevalent Cases of Increased LDLc* (?115mg/dL to ?160mg/dL), Ages ?20 Years, N (Row %), 2013 72
Table 19: 8MM, Total Prevalent Cases of Very High TG (?500mg/dL), Both Sexes, Ages ?20 Years, N, 2013-2023 75
Table 20: 8MM, Age-Specific Total Prevalent Cases of Very High TG (?500mg/dL), Both Sexes, N (Row %), 2013 76
Table 21: 8MM, Sex-Specific Total Prevalent Cases of Very High TG (?500mg/dL), Ages ?20 Years, N (Row %), 2013 78

1.2 List of Figures

Figure 1: 8MM, Total Prevalent Cases of Dyslipidemia, Both Sexes, Ages ?20 Years, N, 2013-2023 61
Figure 2: 8MM, Age-Specific Total Prevalent Cases of Dyslipidemia, Both Sexes, Ages ?20 Years, N, 2013 63
Figure 3: 8MM, Sex-Specific Total Prevalent Cases of Dyslipidemia, Ages ?20 Years, N, 2013 64
Figure 4: 8MM, Age-Standardized Total Prevalence of Dyslipidemia (%), Ages ?20 Years, by Sex, 2013 65
Figure 5: 8MM, Total Prevalent Cases of Familial Hypercholesterolemia, Both Sexes, Ages ?20 Years, N, 2013-2023 67
Figure 6: 8MM, Total Prevalent Cases of Increased LDLc* (?115mg/dL to ?160mg/dL), Both Sexes, Ages ?20 Years, N, 2013-2023 68
Figure 7: 8MM, Age-Specific Total Prevalent Cases of Increased LDLc* (?115mg/dL to ?160mg/dL), Both Sexes, Ages ?20 Years, N, 2013 71
Figure 8: 8MM, Sex-Specific Total Prevalent Cases of Increased LDLc* (?115mg/dL to ?160mg/dL), Ages ?20 Years, N, 2013 73
Figure 9: 8MM, Age-Standardized Total Prevalence of Increased LDLc (?115mg/dL to ?160mg/dL)* (%), Ages ?20 Years, by Sex, 2013 74
Figure 10: 8MM, Total Prevalent Cases of Very High TG (?500mg/dL), Both Sexes, Ages ?20 Years, N, 2013-2023 75
Figure 11: 8MM, Age-Specific Total Prevalent Cases of Very High TG (?500mg/dL), Both Sexes, Ages ?20 Years, N, 2013 77
Figure 12: 8MM, Sex-Specific Total Prevalent Cases of Very High TG (?500mg/dL), Ages ?20 Years, N, 2013 78
Figure 13: 8MM, Age-Standardized Total Prevalence of Very High TG (?500mg/dL) (%), Ages ?20 Years, by Sex, 2013 79

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Dyslipidemia  - Market Insights, Epidemiology and Market Forecast-2023

Dyslipidemia  - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Dyslipidemia - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global ...

Global Blood cholesterol monitors Market Research Report 2016

Global Blood cholesterol monitors Market Research Report 2016

  • $ 2850
  • Industry report
  • September 2016
  • by 9Dimen Research

2016 Global Blood cholesterol monitors Industry Report is a professional and in-depth research report on the world's major regional market conditions of the Blood cholesterol monitors industry, focusing ...

2016 Global and Chinese Cholesterol Industry Market Research Report

2016 Global and Chinese Cholesterol Industry Market Research Report

  • $ 2800
  • Industry report
  • September 2016
  • by Prof Research

The 'Global and Chinese Cholesterol Industry, 2011-2021 Market Research Report' is a professional and in-depth study on the current state of the global Cholesterol industry with a focus on the Chinese ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.